GlassScriptPhysician profile
Jerry Winkler
NPI 1851365910
$483.81
in general payments reported to CMS, 2019-2025
9 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250.00 | 2025 | Imdelltra (Amg757) |
| Janssen Biotech, INC. | $52.60 | 2025 | Rybrevant, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $47.79 | 2025 | Imfinzi, Enhertu |
| Jazz Pharmaceuticals INC. | $30.23 | 2025 | |
| Abbvie INC. | $30.21 | 2025 | |
| Incyte Corporation | $26.14 | 2025 | Jakafi |
| Karyopharm Therapeutics INC. | $19.22 | 2025 | Xpovio |
| Astellas Pharma US INC | $15.70 | 2025 | Vyloy |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.